INT55470

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 1994
Last Reported 2011
Negated 2
Speculated 2
Reported most in Body
Documents 16
Total Number 18
Disease Relevance 12.51
Pain Relevance 2.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Mtor) mitochondrion (Mtor) Golgi apparatus (Mtor)
endoplasmic reticulum (Mtor) nucleus (Mtor) kinase activity (Mtor)
Anatomy Link Frequency
neuronal 1
liver 1
neurons 1
Brains 1
Mtor (Mus musculus)
Pain Link Frequency Relevance Heat
Paracetamol 12 100.00 Very High Very High Very High
antagonist 7 99.96 Very High Very High Very High
COX2 30 98.80 Very High Very High Very High
Pyramidal cell 18 96.32 Very High Very High Very High
cva 11 94.62 High High
imagery 56 92.40 High High
headache 2 90.84 High High
positron emission tomography 40 85.56 High High
palliative 3 81.76 Quite High
cryotherapy 1 73.60 Quite High
Disease Link Frequency Relevance Heat
Parkinson's Disease 177 99.82 Very High Very High Very High
Mantle-cell Lymphoma 33 99.16 Very High Very High Very High
Cancer 273 98.92 Very High Very High Very High
Polycystic Kidney Disease 13 98.68 Very High Very High Very High
Insulin Resistance 14 98.16 Very High Very High Very High
Recurrence 9 98.08 Very High Very High Very High
Hepatocellular Cancer 76 97.96 Very High Very High Very High
Disease 349 97.04 Very High Very High Very High
Obesity 99 97.04 Very High Very High Very High
Apoptosis 46 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immunohistochemically, most of the tumor cells were immunoreactive for anti-phospho-mammalian target of rapamycin (mTOR) and phospho-S6 ribosomal protein antibodies.
Regulation (target) of mTOR associated with cancer
1) Confidence 0.24 Published 2007 Journal J. Neurosurg. Section Abstract Doc Link 18459885 Disease Relevance 1.37 Pain Relevance 0.09
Western blot analysis with the anti-58 antibody of liver cytosol from unchallenged mice showed no apparent changes in the levels of the 58-kDa major APAP target protein with CFB treatment.
Neg (no) Regulation (changes) of APAP target protein in liver associated with paracetamol
2) Confidence 0.07 Published 1994 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 7992315 Disease Relevance 0.23 Pain Relevance 0.72
Mammalian Tor (mTOR) pathway was activated, confirmed by Frap1, Rheb and Akt1 up-regulation.
Regulation (regulation) of Frap1
3) Confidence 0.04 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2674043 Disease Relevance 0.22 Pain Relevance 0
According to real-time PCR data, genes encoding: connexin 43 (Gja1), and Frap1 was found not to be regulated by diet (Table 2).


Regulation (regulated) of Frap1
4) Confidence 0.04 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2674043 Disease Relevance 1.23 Pain Relevance 0
Compared to the unimpaired neurons in the control cases, in DLB brains, mTor and LC3 immunoreactivity were more abundant in neurons displaying ?
Regulation (immunoreactivity) of mTor in neurons associated with parkinson's disease
5) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 0.71 Pain Relevance 0.03
Another potential candidate that integrates growth factor and nutrient signaling within the PI3K/Akt pathway is mammalian target of rapamycin (mTOR).
Regulation (target) of mTOR
6) Confidence 0.03 Published 2006 Journal Age (Dordr) Section Body Doc Link PMC2464727 Disease Relevance 0.72 Pain Relevance 0
In contrast, in DLB cases levels of neuronal mTor immunoreactivity were increased (Figure 2C, G), while the levels of neuronal Atg7 immunolabeling were reduced (Figure 2F, G).
Regulation (immunoreactivity) of mTor in neuronal associated with parkinson's disease
7) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 0.90 Pain Relevance 0.08
Alterations in the Levels of mTor and Atg7 Are Associated with Lysosomal Alterations the Brains of DLB Patients
Regulation (Alterations) of mTor in Brains associated with parkinson's disease
8) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 0.38 Pain Relevance 0.07
To assess whether the combined suppression of both VEGF activity by bevacizumab and VEGF expression by targeting mTOR via rapamycin (RAPA) results in the inhibition of HCC tumor, we created an orthotopic xenograft HCC model.
Spec (whether) Regulation (targeting) of mTOR associated with cancer and hepatocellular cancer
9) Confidence 0.02 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2719751 Disease Relevance 1.10 Pain Relevance 0.37
Currently, embolization is proposed as the first choice of intervention for symptomatic AMLs or to prevent hemorrhage when AMLs exceed 4 cm in diameter.[4,5] Patients with TSC have however a 40% recurrence rate of symptomatic AMLs with a median time interval from embolization to recurrence of approximately 79 months.[6] As genes mutations in TSC result in activation of the mammalian target of rapamycin (mTOR), therapy with sirolimus, a suppressor of the mTOR signaling, has been recently implemented in order to reduce the size of AML and to prevent retroperitoneal bleeding.[7] As result of the treatment, AMLs regressed during the therapy but increased again once the therapy was stopped.
Regulation (target) of mTOR associated with myeloid leukemia, hemorrhage, cva and recurrence
10) Confidence 0.01 Published 2008 Journal Cases J Section Body Doc Link PMC2636789 Disease Relevance 1.48 Pain Relevance 0.24
In order to examine potential mechanisms by which antioxidants may influence autophagy, we examined their effect on the mTOR pathway, a classical negative regulator of autophagy, by looking for changes in the phosphorylation status of an mTOR kinase substrate 4E binding protein 1 (4E-BP1) and a protein dependent on mTOR substrate kinase activity, ribosomal protein S6 (S6).
Regulation (dependent) of mTOR
11) Confidence 0.01 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2916709 Disease Relevance 0.12 Pain Relevance 0
Menadione had the opposite effect of thiol antioxidants by enhancing JNK and Bcl-2 phosphorylation, but had no effect on mTOR activity or Beclin-1 expression (Fig. 6F).
Neg (no) Regulation (effect) of mTOR
12) Confidence 0.01 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2916709 Disease Relevance 0.12 Pain Relevance 0
The mammalian target of rapamycin (mTOR), one of the targets of the PTEN/Pi3K pathway, is a conserved kinase that regulates central cellular functions in response to environmental signals, such as transcription and translation, mRNA and protein turnover, or autophagy (reviewed in [190, 191]).
Regulation (target) of mTOR
13) Confidence 0.01 Published 2008 Journal PPAR Research Section Body Doc Link PMC2606065 Disease Relevance 0.59 Pain Relevance 0.03
Apart from the popular monoclonal antibodies and small molecules tyrosine kinase inhibitors, other novel compounds being tested in preclinical and clinical studies target mTOR, NF-kappaB, proteasome and histone deacetylase.
Regulation (target) of mTOR
14) Confidence 0.01 Published 2008 Journal Cancer Metastasis Rev. Section Abstract Doc Link 18427734 Disease Relevance 0.46 Pain Relevance 0.08
Since the mammalian target of rapamycin (mTOR) pathway regulates VEGF expression in cancer cells [32], researchers combined BEV and rapamycin in an ovarian cancer xenograft model and found a 94% reduction in tumor growth as well as a prolonged survival [33].
Regulation (target) of mTOR associated with cancer and ovarian cancer
15) Confidence 0.01 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.69 Pain Relevance 0
This study was designed to investigate the effects of the mTOR antagonist rapamycin and the COX 2 inhibitor celecoxib on cell growth and apoptosis in malignant melanoma.
Spec (investigate) Regulation (effects) of mTOR associated with antagonist, cox2, skin cancer and apoptosis
16) Confidence 0.01 Published 2008 Journal Oncol. Rep. Section Abstract Doc Link 18202806 Disease Relevance 0.59 Pain Relevance 0.26
The absence of polycystin permits excessive kinase activity in the mammalian which is the target of rapamycin (mTOR) pathway and the development of renal cysts [26].
Regulation (target) of mTOR associated with polycystic kidney disease
17) Confidence 0.00 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC3017903 Disease Relevance 0.94 Pain Relevance 0.10
Intriguingly, mTOR inhibition affected cyclin D1 proteolysis only in MCL cells in which GSK-3 is under the direct control of mTOR, suggesting that different MCL subsets could be differently responsive to mTOR inhibition.
Regulation (control) of mTOR associated with mantle-cell lymphoma
18) Confidence 0.00 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.67 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox